X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs DIVIS LABORATORIES - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA DIVIS LABORATORIES ABBOTT INDIA/
DIVIS LABORATORIES
 
P/E (TTM) x 40.9 31.8 128.7% View Chart
P/BV x 9.7 5.7 170.3% View Chart
Dividend Yield % 0.7 0.9 81.8%  

Financials

 ABBOTT INDIA   DIVIS LABORATORIES
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
DIVIS LABORATORIES
Mar-17
ABBOTT INDIA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs6,1101,222 500.0%   
Low Rs3,996784 509.7%   
Sales per share (Unadj.) Rs1,552.2153.1 1,013.9%  
Earnings per share (Unadj.) Rs188.839.9 472.7%  
Cash flow per share (Unadj.) Rs196.444.6 440.5%  
Dividends per share (Unadj.) Rs55.0010.00 550.0%  
Dividend yield (eoy) %1.11.0 109.2%  
Book value per share (Unadj.) Rs796.6201.8 394.7%  
Shares outstanding (eoy) m21.25265.47 8.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.36.6 49.7%   
Avg P/E ratio x26.825.1 106.6%  
P/CF ratio (eoy) x25.722.5 114.4%  
Price / Book Value ratio x6.35.0 127.6%  
Dividend payout %29.125.0 116.4%   
Avg Mkt Cap Rs m107,376266,266 40.3%   
No. of employees `0003.39.7 34.1%   
Total wages/salary Rs m3,9374,687 84.0%   
Avg. sales/employee Rs Th9,929.34,175.0 237.8%   
Avg. wages/employee Rs Th1,185.1481.5 246.1%   
Avg. net profit/employee Rs Th1,207.71,089.3 110.9%   
INCOME DATA
Net Sales Rs m32,98540,643 81.2%  
Other income Rs m1,170749 156.2%   
Total revenues Rs m34,15541,392 82.5%   
Gross profit Rs m5,24514,460 36.3%  
Depreciation Rs m1621,233 13.1%   
Interest Rs m3823 169.0%   
Profit before tax Rs m6,21513,953 44.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2033,349 65.8%   
Profit after tax Rs m4,01210,604 37.8%  
Gross profit margin %15.935.6 44.7%  
Effective tax rate %35.424.0 147.7%   
Net profit margin %12.226.1 46.6%  
BALANCE SHEET DATA
Current assets Rs m22,65540,105 56.5%   
Current liabilities Rs m6,6816,595 101.3%   
Net working cap to sales %48.482.5 58.7%  
Current ratio x3.46.1 55.8%  
Inventory Days Days65119 54.6%  
Debtors Days Days2981 36.1%  
Net fixed assets Rs m83519,995 4.2%   
Share capital Rs m213531 40.0%   
"Free" reserves Rs m16,71553,043 31.5%   
Net worth Rs m16,92853,574 31.6%   
Long term debt Rs m00-   
Total assets Rs m24,16261,585 39.2%  
Interest coverage x163.7618.4 26.5%   
Debt to equity ratio x00-  
Sales to assets ratio x1.40.7 206.9%   
Return on assets %16.817.3 97.1%  
Return on equity %23.719.8 119.7%  
Return on capital %36.926.1 141.6%  
Exports to sales %00-   
Imports to sales %025.2 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA10,259 0.0%   
Fx inflow Rs m36935,384 1.0%   
Fx outflow Rs m3,80710,399 36.6%   
Net fx Rs m-3,43824,985 -13.8%   
CASH FLOW
From Operations Rs m1,52711,493 13.3%  
From Investments Rs m-2,148-11,372 18.9%  
From Financial Activity Rs m-1,024-93 1,100.2%  
Net Cashflow Rs m-1,64628 -5,794.4%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 11.8 66.9%  
FIIs % 0.1 19.0 0.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 17.2 99.4%  
Shareholders   18,270 31,796 57.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  GSK PHARMA  PLETHICO PHARMA  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Up Over 240 Points; Rupee Touches Record Low(12:30 pm)

After opening the day in the green, stock markets in India have continued their momentum and are presently trading on a positive note.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY18); Net Profit Up 137.9% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 137.9% YoY). Sales on the other hand came in at Rs 8 bn (up 10.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Should You Buy These Mouthwatering High Dividend Stocks?(Profit Hunter)

Aug 1, 2018

Many stocks are yielding dividends even upwards of 4%-5%. Here are the kinds you should pick, and the ones to avoid.

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

NFO - Axis Equity Hybrid Fund: A Worthy Proposition?(Outside View)

Aug 1, 2018

PersonalFN explains if NFO: Axis Equity Hybrid Fund, would be a worthy proposition currently.

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Aug 14, 2018 02:03 PM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS